# HB1801 Combined Treatment of HER2-positive Breast Cancer

> **NCT07116824** · PHASE2 · NOT_YET_RECRUITING · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 80 (estimated)

## Conditions studied

- HER2-positive Breast Cancer

## Interventions

- **DRUG:** HB1801
- **DRUG:** Trastuzumab
- **DRUG:** Pertuzumab
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT07116824
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-15
- **Primary completion:** 2026-07-15
- **Final completion:** 2027-11-07
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07116824

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07116824, "HB1801 Combined Treatment of HER2-positive Breast Cancer". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT07116824. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*